Samsung Biologics Co., Ltd. Overview
Pro stress-test →Samsung Biologics is a biopharmaceutical company engaged in drug development and manufacturing services, operating through two segments: Biopharmaceutical Development and Commercialization, and Contract Development and Manufacturing Organization (CDMO). The company generates the majority of its revenue from the CDMO segment, positioning it as a leading CDMO offering end-to-end integrated services ranging from late discovery to commercial manufacturing.
Strategic Profile
Pro stress-test →Samsung Biologics recently completed the spin-off of Samsung Bioepis, reinforcing its strategic focus as a pure-play CDMO. With combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 liters from an acquisition of a Maryland facility, the company leverages cutting-edge technologies to advance diverse modalities including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. The company received EcoVadis' Platinum Sustainability Rating in January 2026, placing it in the top one percent of companies evaluated globally.
Competitive Landscape
Pro stress-test →Samsung Biologics operates in the CDMO sector alongside competitors providing contract manufacturing, cell line development, and process development services for biopharmaceutical companies. The company competes on manufacturing capacity, technological capability, regulatory expertise, and geographic reach in a highly consolidated market dominated by specialized CDMOs and larger contract manufacturers.
Industry Context
Samsung Biologics Co., Ltd. operates in Contract Development and Manufacturing Organization (CDMO) / Biopharmaceutical Manufacturing.
Key facts
Founded: 2011 · Headquarters: Incheon, South Korea · Employees: 4,770 · Revenue: $3.9B (TTM) · Market cap: $54.5B